目的 探讨血管内皮生长因子受体2(VEGFR-2)、血小板衍生生长因子受体β(PDGFR-β)和c-MET在肝细胞癌(HCC)中表达的临床意义及对预后的影响.方法 应用免疫组织化学法检测93例HCC组织中VEGFR-2、PDGFR-β和c-MET的表达,分析其与临床病理特征和预后的关系.结果 VEGFR-2、PDGFR-β和c-MET在HCC组织中的高表达率分别为86.0％、19.4％和80.6％.VEGFR－2表达与性别、HBsAg状态、分化程度、肝硬化有关(P＜0.05),PDGFR-β表达与AFP、肿瘤数目、肝硬化有关(P＜0.05),c-MET表达与临床病理特征无关.Cox多因素回归分析显示,65例服用索拉非尼患者的无进展生存期(PFS)与年龄(P=0.047)有关,总生存期(OS)与HBsAg(P =0.037)、AFP(P=0.015)和肿瘤大小(P =0.003)有关；PDGFR-β表达水平与OS相关(P=0.046),c-MET与PFS相关(P=0.01).结论 VEGFR-2在HCC合并肝硬化的患者中存在高表达,PDGFR-β高表达是HCC的预后不良指标,c-MET可能是HCC患者服用索拉非尼疗效的一个预测指标.%Objective To explore the clinical significance and prognostic values of VEGFR-2,PDGFR-B and c-MET in patients with hepatocellular carcinoma (HCC). Methods The expression of VEGFR-2, PDGFR-p and c-MET in 93 HCC patients was examined by immunohislochemistry(IHC), and the correlation between clinical characteristics and progrosis was analyzed. Results The over-expression rates of VEGFR-2, PDGFR-B and c-MET in HCC were 86.0% , 19.4% and 80.6% , respectively. The expression of VEGFR-2 was related with sex, hepatitis B surface antigen(HBsAg) status, differentiation and hepatic cirrhosis ( P < 0. 05 ). The expression of PDGFR-fJ was related with a-feloprotein( AFP), number of tumor and hepatic cirrhosis (P < 0.05). There was no significant relationship between the expression of e-MET and clinieopathological factors. Cox regression analysis showed that in 65 patients taking sorafenib, the progress free survival (PFS) was related to age (P-0. 047), and the overall survival (OS) was related to HBsAg(P= 0.037), AFP(P = 0.015) and tumor size(P =0.003). The expression of PDGFR-0 was related with OS (P = 0.046). The expression of c-MET was related to PFS (P =0. 01 ). Conclusion The expression level of VEGFR-2 is higher in HCC patients with hepatic cirrhosis. PDGFR-fi is a biomarker for the poor prognosis in HCC patients. c-MET may be a prognostic factor to predict the therapeutic effect of HCC patients who have taken sorafenib.
展开▼
